BackgroundBile duct carcinoma is a common digestive tract tumor with high morbidity and mortality. As a kind of important non-coding RNA, microRNA (miR) plays an important role in post-transcriptional regulation. MiR-122 is the most abundant miR in the liver. Multiple studies have shown that miR-122 level is reduced in a variety of liver tumors and can be used as a specific marker for liver injury. P53 is a classic tumor suppressor gene that can induce tumor cell apoptosis through various pathways. Whether miR-122 affects p53 in bile duct carcinoma still needs investigation.Material/MethodsmiR inhibitor or mimics was transfected to bile duct carcinoma cells to evaluate its function on proliferation, invasion, apoptosis, and p53 expression.ResultsMiR-122 overexpression reduced cell invasion and migration ability, and inhibited cell apoptosis and p53 expression. Inhibiting miR-122 caused the opposite results.ConclusionsUpregulating miR-122 can suppress bile duct carcinoma cell proliferation and induce apoptosis. MiR-122 could be used as a target for bile duct carcinoma treatment, which provides a new strategy for cholangiocarcinoma patients.
Background Increasing evidence has demonstrated the involvement of microRNAs in pathogenesis of Hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). The aim of this study was to analyze whether miR-487b can be used as diagnostic and prognostic biomarkers for the HBV-related HCC and to explore its effect on the biological function of HCC. Methods The expression levels of miR-487b in the serum of all subjects were detected by the real-time fluorescence quantitative PCR (qRT-PCR). The diagnostic value of miR-487b in serum was assessed by the receiver operating characteristic (ROC) curve. The relationship between miR-487b and clinical data of patients was analyzed by a Chi-square test. The prognostic value of miR-487b in HCC was assessed by Cox regression analysis and Kaplan-Meier survival. Moreover, the CCK-8 and Transwell assays were performed to investigate the effect of miR-487b on HBV-related HCC function. Results Our data indicated that miR-487b in HCC patients was significantly higher than in CHB patients and healthy controls. Meanwhile, ROC curve showed that miR-487b had high specificity and sensitivity in the diagnosis of HBV-related HCC. MiR-487b can significantly distinguish between HCC patients and healthy controls, and can differentiate HCC patients from chronic hepatitis B (CHB) patients. Cox regression analysis showed that miR-487b was an independent risk factor. Overexpression of miR-487b was associated with Tumor Node Metastasis stage (TNM) stage and Barcelona clinic liver cancer (BCLC) stage in HCC patients. Cell function experiments demonstrated that upregulated miR-487b could promote cell proliferation, migration, and invasion. Conclusion Combined the results of the current study demonstrate that the upregulation of serum miR-487b may serve as a promising noninvasive diagnostic biomarker for HBV-related HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.